2016 ANNUAL REVIEW Ministry of Science and Technology

b. International cooperation and training (a) A research team from National Taiwan University joined forces with R&D teams from Poland, Italy, and Spain in the multinational, multilateral Translational Cancer Research ( TRANSCAN- 2 ) campa i gn , wh i ch was approved by the EU's European Union Horizon 2020 Programme in October 2016. Domestic projects will implemented with funding support from MOST. Apart from showing the international community's respect for the translation cancer research being conducted in Taiwan, the implementation of TRANSCAN-2 projects is also an important milestone in Taiwan's international cooperation and diplomacy. (b) The program hosted the 2 nd Taiwan-Japan Bilateral Symposium, which was held May 27-28, 2016 and was on the topic of "Cancer Translational Research and Cancer Entry research". Both parties' speakers signed 13 bilateral confidentiality agreements, and speakers from Taiwan presented 11 papers, which will serve as references for subsequent R&D in relevant fields. (c) In March 2016, the program received an invitation from Japan's Academic Research Organization (ARO) to participate in ARO's "Global Clinical Trial Consortium," which is conducting preliminary discussions with Asian countries (Japan, Korea, Singapore, Taiwan), European countries (France), and the US concerning "simultaneous worldwide marketing approval of drugs" as the goal of multinational, multi-center cooperation, and cooperation in the implementation of simultaneous clinical trials employing each country's funding approach. (d) The program brought about collaboration between Takeda—Japan's largest multinational pharmaceutical company—and the Academia Sinica, and the two parties completed signing of a collaboration contract on August 26, 2016. This collaboration is Takeda's first early R&D collaboration case involving a research organization in Taiwan, and shows international industry's respect for the R&D technology of Taiwan's academic and research organizations, which is gradually reaching parity with international levels. (e) The program brought about the joint implementat- ion of a collaborative cancer research project personnel helped found TCTC or have joined it. TCTC is effectively coordinating and integrating domestic clinical resources, collaborating in the implementation of multi-center trials, and cultivating clinical trial teams implementing international multi-center or domestic multi-hospital trials. Thus far, TCTC has implemented 15 clinical trials cooperation alliances for specific diseases, and is currently managing 13 of these. According to a survey performed at the end of October 2016, 275 projects underway at that time had been commissioned by international pharmaceutical firms, 69 projects had been commissioned by domestic firms, and TCTC playing a leading role 80 of both types of projects. In order to enhance the quality and efficiency of clinical trials, this program also provides the bioinformatics, statistics, legal, and regulatory consulting services needed by clinical trials, and has established a joint ethics review and clinical trial contract signing acceleration mechanism. By ensuring that trials can be completed in as timely a manner as possible, the program will speed up the new drug R&D process. (5) Industrialization promotion and international cooperation group a. Industrialization promotion performance This group completed 11 technology market assessment reports/case analysis reports, 17 patent retrieval reports/patent analysis reports, 13 patent/technical market consulting service reports, and assisted with 19 patent applications (including four Patent Cooperation Treaty patents and 14 US provisional patents, and one Taiwan patents) in 2016. Furthermore, the group used the iBM assessment model (IP, Business, Market) to perform an inventory of 150 results of the National Research Program for Biopharmaceuticals results, and found that 20 case sources possess continuing commercialization potential; the group will continue to perform tracking and assist the program in performing commercialization of technology. The group further held two IPR committee meetings and three case R&D results recruiting and explanatory meetings, jointly promoted 38 industry- academic collaboration/technological collaboration/ technology transaction cases (including completion of contract signing for four technology licensing cases and two industry-academic collaboration cases), helped five companies to increase capital, and completed 39 commercial and legal service cases. These efforts induced about approximately NT$304.2 million in corporate investment and created 17 jobs in industry. MOST Ministry of Science and Technology Ministry of Science and Technology 54 2016 ANNUAL REVIEW